Bristol-Myers Squibb Company (BMY)
| Market Cap | 95.95B |
| Revenue (ttm) | 47.70B |
| Net Income (ttm) | 5.05B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.49 |
| PE Ratio | 18.96 |
| Forward PE | 7.38 |
| Dividend | $2.48 (5.26%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 8,227,215 |
| Open | 46.72 |
| Previous Close | 46.69 |
| Day's Range | 46.50 - 47.17 |
| 52-Week Range | 42.96 - 63.33 |
| Beta | 0.36 |
| Analysts | Hold |
| Price Target | 57.64 (+22.27%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.64, which is an increase of 22.27% from the latest price.
News
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol-Myers Squibb: Not As Cheap As It Might Seem
At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ava...
8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025...
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September...
8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars
I use YCharts' Value Score and Ben Graham Formula to identify large-cap value stocks offering strong intrinsic value and stable dividends. Analyst forecasts suggest top-ten GASV 'Dogs' could deliver 1...
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025.
Final Trades: ServiceNow, Bristol Myers and Live Nation
The Investment Committee give you their top stocks to watch for the second half.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D...
Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers
Many high-yield S&P 500 stocks are risky, but 19 'safer' dividend dogs have strong free cash flow to support payouts and are worth considering. Analyst forecasts suggest the top ten S&P 500 dividend d...
Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends
The Dividend Harvesting Portfolio rebounded strongly, with profitability up 8.06% and total dividend income now at 19.77% of invested capital. I remain bullish on the S&P 500 reaching 7,000 this year,...
3 SWANs On Sale
Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li...
3 Dividend Stocks for August 2025
These three dividend payers have an average yield of 4.5%.
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused ...
Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).
Bristol-Myers Squibb: Buy The Weakness
Bristol-Myers Squibb faces political pressure on U.S. drug prices, but I see the risk as manageable given its strong fundamentals. The company's growth portfolio now exceeds half of revenue, offsettin...
Bristol-Myers Squibb: Declines Have Gone Too Far
Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum. Despite margin compression and profitability con...
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising ove...
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Bristol-Myers Squibb Company beat Q2 2025 revenue expectations and raised full-year guidance, but EPS guidance was lowered and shares remain under pressure. The company's growth portfolio is expanding...
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappointm...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...